Tesamorelin is a synthesized GHRH peptide derivative and is clinically used for HIV-associated lipodystrophy, a condition characterized by a fast-acting accumulation of fat in the abdominal area.
Tesamorelin is being researched for its ability to stimulate the pituitary gland into producing more growth hormones, with its demonstrated ability to reduce visceral adipose tissue or deep abdominal fat associated with a number of concerning health risks.